{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:02:04Z","timestamp":1771272124664,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13300-025-01825-5","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:28:51Z","timestamp":1765261731000},"page":"231-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012\u20132023: A US Cohort Study"],"prefix":"10.1007","volume":"17","author":[{"given":"Catherine B.","family":"Johannes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anam M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Ziemiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bradley","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vizcaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus G.","family":"Oberprieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"1","key":"1825_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"10075","key":"1825_CR2","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238\u201352.","journal-title":"Lancet"},{"key":"1825_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.672350","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng Y, Li N, Wu Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front Endocrinol (Lausanne). 2021;12:672350. https:\/\/doi.org\/10.3389\/fendo.2021.672350.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1825_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.ajkd.2008.11.019","volume":"53","author":"AS Levey","year":"2009","unstructured":"Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53(3):522\u201335. https:\/\/doi.org\/10.1053\/j.ajkd.2008.11.019.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"1825_CR5","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.2337\/dc24-S011","volume":"47","author":"American Diabetes Association","year":"2024","unstructured":"American Diabetes Association. American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Suppl 1):S219\u201330.","journal-title":"Diabetes Care"},{"issue":"102","key":"1825_CR6","first-page":"S1","volume":"2022","author":"KDIGO","year":"2022","unstructured":"KDIGO. Kidney Disease: Improving Global Outcomes Work Group (KDIGO) 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;2022(102):S1-127.","journal-title":"Kidney Int"},{"issue":"1","key":"1825_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01899-0","volume":"22","author":"U Kintscher","year":"2023","unstructured":"Kintscher U, Edelmann F. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023;22(1):162.","journal-title":"Cardiovasc Diabetol"},{"key":"1825_CR8","unstructured":"Bayer HealthCare Pharmaceuticals Inc. KERENDIA (finerenone) tablets, for oral use. Highlights of prescribing information. 2022. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Kerendia_PI.pdf. Accessed 6 Nov 2023."},{"key":"1825_CR9","unstructured":"Janssen Pharmaceuticals, Inc. INVOKANA (canagliflozin) tablets, for oral use. Highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204042s034lbl.pdf. Accessed 29 May 2025."},{"key":"1825_CR10","unstructured":"AstraZeneca. Press release: Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes. 2021.https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/farxiga-approved-in-the-us-for-ckd.html#!. Accessed"},{"key":"1825_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573.","journal-title":"BMJ"},{"issue":"10","key":"1825_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1825_CR13","unstructured":"Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use. Highlights of prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209637s025lbl.pdf. Accessed 13 Feb 2025."},{"key":"1825_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. https:\/\/doi.org\/10.1136\/bmj-2022-074068.","journal-title":"BMJ"},{"key":"1825_CR15","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Approval package for Application number: 215341Orig1s000. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215341Orig1s000Approv.pdf. Accessed 25 Apr 2025."},{"issue":"1","key":"1825_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02344-w","volume":"24","author":"NG Oberprieler","year":"2024","unstructured":"Oberprieler NG, Pladevall-Vila M, Johannes C, et al. FOUNTAIN: a modular research platform for integrated real-world evidence generation. BMC Med Res Methodol. 2024;24(1):224.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"1825_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13300-024-01671-x","volume":"16","author":"CB Johannes","year":"2025","unstructured":"Johannes CB, Ziemiecki R, Pladevall-Vila M, et al. Clinical profile and treatment adherence in patients with type 2 diabetes and chronic kidney disease who initiate an SGLT2 inhibitor: a multi-cohort study. Diabetes Ther. 2025;16(2):205\u201326. https:\/\/doi.org\/10.1007\/s13300-024-01671-x.","journal-title":"Diabetes Ther"},{"issue":"5","key":"1825_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13300-025-01717-8","volume":"16","author":"M Pladevall-Vila","year":"2025","unstructured":"Pladevall-Vila M, Ziemiecki R, Johannes CB, et al. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: a multinational cohort study. Diabetes Ther. 2025;16(5):931\u201354. https:\/\/doi.org\/10.1007\/s13300-025-01717-8.","journal-title":"Diabetes Ther"},{"issue":"8","key":"1825_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jama.2015.0602","volume":"313","author":"AS Levey","year":"2015","unstructured":"Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313(8):837\u201346.","journal-title":"JAMA"},{"issue":"25","key":"1825_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"10","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;10(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"6","key":"1825_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","volume":"31","author":"WP Glasheen","year":"2017","unstructured":"Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI)\u2014update and ICD-10 translation. J Diabetes Complications. 2017;31(6):1007\u201313. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.02.018.","journal-title":"J Diabetes Complications"},{"key":"1825_CR22","doi-asserted-by":"crossref","unstructured":"Yano Y, Okami S, Kanegae H, et al. Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes\u2014a hospital-based cohort study in Japan. Diabetes Obes Metab. 2025;27(7):3714\u201324.","DOI":"10.1111\/dom.16394"},{"issue":"15","key":"1825_CR23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;8(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"15","key":"1825_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"8","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;8(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"1825_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The Empa-Kidney Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"18","key":"1825_CR26","first-page":"e895","volume":"3","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;3(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"9","key":"1825_CR27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.cardfail.2023.12.018","volume":"30","author":"AS Varshney","year":"2024","unstructured":"Varshney AS, Calma J, Kalwani NM, et al. Uptake of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure: insights from the Veterans Affairs Healthcare system. J Card Fail. 2024;30(9):1086\u201395. https:\/\/doi.org\/10.1016\/j.cardfail.2023.12.018.","journal-title":"J Card Fail"},{"issue":"1","key":"1825_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jamacardio.2024.4489","volume":"1","author":"M Abdel Jawad","year":"2025","unstructured":"Abdel Jawad M, Spertus JA, Ikeaba U, et al. Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiol. 2025;1(1):89\u201394.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1825_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.amjms.2024.07.011","volume":"368","author":"A Tuersun","year":"2024","unstructured":"Tuersun A, Hou G, Cheng G. Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: an update systematic review and meta-analysis. Am J Med Sci. 2024;368(6):579\u201388. https:\/\/doi.org\/10.1016\/j.amjms.2024.07.011.","journal-title":"Am J Med Sci"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01825-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:55Z","timestamp":1771268635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01825-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01825-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fangfang Liu and Nikolaus G. Oberprieler are employees of Bayer, which funded this study. David Vizcaya was an employee of Bayer at the time the research was conducted. Catherine B. Johannes, Anam M. Khan, Ryan Ziemiecki, and J. Bradley Layton are or were employees of RTI Health Solutions, which received research funding for this study from Bayer. Craig I. Coleman has received grant funding and consulting fees from Bayer AG and AstraZeneca Pharmaceuticals. Csaba P. Kovesdy received consulting fees from Abbott, Akebia, Ardelyx, Astra Zeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, CSL Vifor, GSK, Pharmacosmos, ProKidney, Renibus and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was deemed not to constitute research involving human subjects according to 45 Code of Federal Regulations 46.102(f) and deemed exempt from board oversight and from full review by the RTI International institutional review board. Data from Optum\u2019s de-identified Clinformatics\n                      \u00ae\n                      Data Mart Database (Optum\n                      \u00ae\n                      CDM) are compliant with the Health Insurance Portability and Accountability Act of 1996, and the study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. No permission was required for access to or use of Optum\n                      \u00ae\n                      CDM. Patient consent for participation and patient consent for publication were not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}